09/14/2026
The treatment landscape for obstructive sleep apnea is evolving. The FDA’s approval of Zepbound (tirzepatide) for OSA in adults with obesity has introduced a new treatment option.
While GLP-1–based therapies may benefit appropriate patients, oral appliance therapy continues to play an important role in managing sleep-disordered breathing.
What does this mean for oral appliance therapy and dental sleep medicine practices?
Our latest blog explores the evolving treatment landscape and what providers should consider.
👉 Read more: https://appnea.ai/blogs/glp-1s-after-zepbound-what-tirzepatide-approval-means-for-oral-appliance-therapy/
hashtag hashtag hashtag hashtag hashtag hashtag
APP-NEA uses deep machine learning for improved sleep apnea treatment